mirabegron mirabegron mirabegron, sold under the brand name myrbetriq among others, is a medication used to treat overactive bladder. its benefits are similar to antimuscarinic medication such as solifenacin or tolterodine. it is taken by mouth. mirabegronclinical datatrade namesmyrbetriq, betanis, betmiga, othersother namesym-178ahfs/drugs.commonographmedlineplusa612038license data eu ema: by inn us dailymed: mirabegron us fda: mirabegron pregnancycategory au: b3 routes ofadministrationby mouth (tablets)atc codeg04bd12 (who) legal statuslegal status au: s4 (prescription only) uk: pom (prescription only) us: ℞-only eu: rx-only in general: ℞ (prescription only) pharmacokinetic databioavailability29–35%protein binding71%metabolismliver via (direct) glucuronidation, amide hydrolysis, and minimal oxidative metabolism in vivo by cyp2d6 and cyp3a4. some involvement of butylcholinesteraseelimination half-life50 hoursexcretionurine (55%), faeces (34%)identifiers iupac name 2-(2-amino-1,3-thiazol-4-yl)-n-amino}ethyl)phenyl]acetamide cas number223673-61-8pubchem cid9865528drugbankdb08893chemspider8041219uniimvr3jl3b2vkeggd09535chebichebi:65349chemblchembl2095212echa infocard100.226.392 chemical and physical dataformulac21h24n4o2smolar mass396.51 g·mol−13d model (jsmol)interactive image smiles o=c(nc1ccc(cc1)ccnc(o)c2ccccc2)cc3nc(sc3)n inchi inchi=1s/c21h24n4o2s/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26h,10-13h2,(h2,22,25)(h,24,27)/t19-/m0/s1key:pbapppcecjkmcm-ibgzpjmesa-n common side effects include high blood pressure, headaches, and urinary tract infections. other significant side effects include urinary retention, irregular heart rate, and angioedema. it works by activating the β3 adrenergic receptor in the bladder, resulting in its relaxation. mirabegron is the first clinically available beta-3 agonist with approval for use in adults with overactive bladder. mirabegron was approved for medical use in the united states and in the european union in 2012. in 2020, it was the 160th most commonly prescribed medication in the united states, with more than 3 million prescriptions. it is available as a generic medication. in the united kingdom it is less preferred to antimuscarinic medication such as oxybutynin. medical uses myrbetriq 50 mg both sides mirabegron is used is in the treatment of overactive bladder. it works equally well to antimuscarinic medication such as solifenacin or tolterodine. in the united kingdom it is less preferred to these agents. mirabegron is also indicated to treat neurogenic detrusor overactivity (ndo), a bladder dysfunction related to neurological impairment, in children ages three years and older. adverse effects adverse effects by incidence: very common (>10% incidence) adverse effects include: elevated blood pressure common (1–10% incidence) adverse effects include: dry mouth nasopharyngitis urinary tract infection (uti) headache influenza constipation dizziness joint pain cystitis back pain upper respiratory tract infection (urti) sinusitis diarrhea high heart rate fatigue abdominal pain neoplasms (cancers) rare (<1% incidence) adverse effects include: palpitations blurred vision glaucoma indigestion gastritis abdominal distension rhinitis elevations in liver enzymes (ggtp, ast, alt and ldh) renal and urinary disorders (e.g., nephrolithiasis, bladder pain) reproductive system disorders (e.g., vulvovaginal pruritus, vaginal infection) skin and subcutaneous tissue disorders (e.g., urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema) stevens–johnson syndrome associated with increased serum alt, ast and bilirubin urinary retention